About InLight Bio

What we cover

New biomedical science: briefs on recent papers and preprints in organoids, disease models, AI drug design, tumor immunology and cell therapy, autoimmunity, vaccines, antibody engineering, nucleic-acid medicines and precision oncology, each written from the original paper with a DOI link.

China biopharma going global: out-licensing deals, NewCo formation, acquisitions of China-originated assets, and the clinical data that drives their value. Readers are investors, pharma business-development teams and NewCo founders who need a fast, sourced view of China-origin assets and deals.

Each brief gives the headline terms with upfront and milestone payments separated, a short summary of the science and the deal logic, and a link to the original announcement or trade-press source.

Editorial principles

• Sources. Every item links to its original source. Items based only on a press release or secondary coverage say so.
• Deal amounts. Upfront and milestones are listed separately, as publicly disclosed. Nothing here is investment advice.
• Accuracy. Summaries add no facts or numbers beyond the original source.
• Illustrations. Images on deal items and science covers are AI-generated illustrations, not data or journal figures.
• Conflicts. We also run a NewCo partnering business. If a company we cover is a client or counterparty, we disclose it at the top of the item. Sponsored content, if any, is labelled and kept separate from editorial content.
• Corrections. Send corrections to contact@inlightbio.com; we mark corrections on the item.

Publisher

InLight Bio is an independent biomedical science and biopharma deals publication. It publishes the science and deal briefs on this site and runs the reports and NewCo partnering services described on the Services page.

Contact